YAP1 and mesothelioma: Small molecule inhibitors targeting the YAP/TAZ-TEAD transcription factor complexes have shown promising preclinical efficacy in mouse models of mesothelioma; these are undergoing clinical evaluation in trials, e.g., ION537 (NCT04659096), VT3989 (NCT04665206), IK-930 (NCT05228015), and IAG933 (NCT04857372) [67].